Abstract
Extracorporeal membrane oxygenation (ECMO) is a modified form of cardiopulmonary bypass. Although early trials were plagued by severe bleeding and high rates of death, subsequent experience with neonates found good survival, and ECMO became an important tool in the care of critically ill infants with respiratory failure. Since the 1980s, expansion to other groups (children, patients with cardiac disease, etc) followed as experience was obtained. Today, there is a rapid growth of ECMO, especially in the adult population. To date, >73,000 patients receiving ECMO have been reported to the international Extracorporeal Life Support Organization registry. This rapid growth in the usage of ECMO has made it possible for it to be included in the management algorithm of certain disease processes, such as ARDS, cardiopulmonary arrest, and septic shock. Significant advances in technology have made it possible to support patients on ECMO for weeks or months with success. Reduction in sedative use and experience with “awake” patients has led to ambulatory and mobile ECMO. Changes in ventilator support while on ECMO, even to the point of extubation, are also occurring. This article will review briefly some of the literature related to criteria for severity of illness before ECMO and related to ECMO care and practice. Issues relating to the use of ECMO as a resuscitative tool in cardiac arrest as well as the controversial topic of volume and outcome will also be presented.
- extracorporeal membrane oxygenation (ECMO)
- pediatric ARDS
- cardiac arrest
- regionalization
- bleeding
- thrombosis
Introduction
Extracorporeal life support, more commonly referred to as extracorporeal membrane oxygenation (ECMO), is a modified form of cardiopulmonary bypass. During ECMO, blood is removed from the venous side and pumped through an extracorporeal circuit containing an artificial lung (membrane oxygenator) in which oxygen is added and carbon dioxide is removed. Blood is then returned to the patient either through the venous side of the circulation in the case of veno venous ECMO or to the arterial side in the case of venoarterial ECMO.1,2
History
ECMO was first successfully used in 1974 in a trauma victim with ARDS.3 Subsequently, ECMO was pioneered as a technique to support term or near-term infants with severe respiratory failure.1,4,5 The efficacy of ECMO has been supported by evidence from one large randomized, controlled trial and several smaller trials. Importantly, the successful use of ECMO in infants established ECMO as a technical success, which led to its expansion in other critical care populations.6–8 The rise of ECMO has led to an increase in the number of publications related to patient care and practice. A description of some of the literature from the recent past is shared below. Readers are encouraged to read the full text of these reports, since only a short summary is presented here.
ECMO in Pediatric ARDS
After 2 years of work, the Pediatric Acute Lung Injury Consensus Conference (PALICC), a group of experts from around the world, published their work on defining pediatric respiratory failure and recommendations for patient care in a supplement of Pediatric Critical Care Medicine.9 Eleven different topics are included, such as epidemiology, severity scoring definitions, pathophysiology, suggestions for best mechanical ventilation and noninvasive ventilation settings, and others. An excerpt from this supplement regarding ECMO is included here.
The accepted wording was confirmed as pediatric ARDS. Mechanical ventilation is the cornerstone of management in pediatric ARDS. However, mechanical ventilation is known to be associated with further lung injury through overdistention, cyclical opening and closing of alveolar units, and oxygen toxicity. Although protective lung strategies are often adopted, these protective thresholds are often exceeded to maintain adequate gas exchange. The role of ECMO in respiratory failure is also discussed. Overall survival of pediatric respiratory failure patients with ECMO averages 56%.
There are no clear agreed-upon criteria for the provision of ECMO support for children with pediatric ARDS. Two clinical measures often used at the bedside are oxygenation index (OI), which is a composite measure of oxygenation and ventilator support [(mean airway pressure × FIO2)100/PaO2] and PaO2/FIO2.10,11 A multi-center review has shown that OI is a predictor of mortality in pediatric respiratory failure.10,12 In the randomized trial of ECMO versus conventional therapy, OI was an independent predictor of mortality. Also in stratified mortality risk, subjects receiving ECMO had significantly lower mortality compared with risk-matched pairs. Because there is a lack of clear criteria applicable to individual patients, decisions to place patients receiving ECMO support are recommended based on serial clinical trends.
Recommendations from the pediatric ARDS consensus group regarding the use of ECMO are as follows.13
Children with severe pediatric ARDS where the cause of the respiratory failure is believed to be reversible or the child is likely to be suitable for consideration for lung transplantation. Strong agreement.
It is not possible to apply strict criteria for the selection of children who will benefit from ECMO in pediatric ARDS. We recommend that children with severe pediatric ARDS should be considered for ECMO when lung-protective strategies result in inadequate gas exchange. Strong agreement.
We recommend that decisions to institute ECMO should be based on a structured evaluation of case history and clinical status. Strong agreement.
We recommend that serial evaluation of ECMO eligibility is more useful than single-point assessment. Strong agreement.
We recommend that careful consideration of quality of life and likelihood of benefit should be assessed. Strong agreement.
Characterizing Acute Lung Injury
Yehya et al14 examined subjects in a single center and compared them with some of the findings in the PALICC reports. The timing of their study, appearing at about the same time as the PALICC supplement, brings some validation to the recommendations by the PALICC group. To characterize variables associated with mortality and ventilator-free days in acute respiratory distress, 283 children with ARDS from a single center were prospectively studied. This study found that initial OI or PaO2/FIO2 might poorly predict outcome. However, the same measurements after the first 24 h of stabilization may be more predictive of lung injury, allowing time for lung recruitment and resuscitation to take place.
In this study, both the PaO2/FIO2 and OI at 24 h were predictive of mortality (P < .001 and P = .002, respectively). Similarly, the worst PaO2/FIO2 and worst OI in the first 24 h were also predictive of mortality (P < .001 and P = .002, respectively). The PaO2/FIO2 and OI at 24 h and worst PaO2/FIO2 and worst OI in the first 24 h were predictive of ventilator-free days from 0 to 28 d and ventilator-free days ≤14 d (P < .001). Increasing extrapulmonary organ failure at ARDS diagnosis correlated with increasing mortality, with the worst 24-h values discriminating the mortality. This was also true for subjects who were immunocompromised. The impact of inhaled nitric oxide therapy on mortality was also examined in subgroup analysis. In this subgroup of subjects, the 24-h PaO2/FIO2 and OI predicted mortality, ventilator-free days, and duration of ventilation in survivors.
Dead-Space Ventilation and Association With Mortality
Another study by Yehya et al15 followed other reports on serial measures of respiratory failure and outcome in children.12,16 This report focuses on the effect of dead space and risk of mortality.15 Dead space is defined as areas of the lung that do not participate in gas exchange either due to lack of ventilation or lack of blood flow. Mechanical ventilation is associated with higher dead space. In studies of adults with ARDS, elevated dead space has been shown to be associated with mortality.15,17–19 Multiple small study cohorts in children with acute hypoxemic respiratory failure have shown an association between increased dead-space ventilation and mortality after controlling for oxygenation defect.17,19 In a large single-center study with 712 children mechanically ventilated for acute hypoxemic respiratory failure, increased dead space was associated with higher mortality. For every increase of 0.1 in dead space, the odds ratio of death was 1.39. This was true as an independent variable, although when controlled for other factors, such as OI, inotrope use, and severity of illness, it was not associated with increased mortality.
International Survey on Ventilation Practices on ECMO
One conundrum regarding the care of patients receiving ECMO is the optimal mechanical ventilator support during the ECMO course. This issue was evaluated in a survey published in 2014 among international centers for patients receiving veno venous ECMO.20 Although surveys must be interpreted with caution, since actual practice may vary from survey results, it does provide new information. Other similar evaluations are also being completed, and whether results will be different should be evident as new publications appear.
The optimal ventilation strategy for mechanical ventilation when patients are receiving veno venous ECMO is unclear, and practices vary widely. To answer this question, Marhong et al20 sent out an international survey to centers registered with the international Extracorporeal Life Support Organization (ELSO). A cross-sectional survey of medical directors and ECMO program coordinators was conducted. The survey collected data on the following domains: (1) patient population and center characteristics; (2) the presence or absence of an explicit mechanical ventilation protocol; (3) mechanical ventilator settings; and (4) weaning practices. A total of 141 responses from 6 continents were included in the final analysis. The primary goal of mechanical ventilation on veno venous ECMO was lung rest (77%). Only 27% of the centers had an explicit mechanical ventilation management protocol. The majority used a controlled mode of ventilation (62%). PEEP levels of >5 cm H2O were used in 80% of centers, whereas 58% of centers targeted PEEP of 6–10 cm H2O. Thirty-one percent of the centers used ultraprotective tidal volumes (<4 mL/kg) for ventilation on ECMO. Weaning from veno venous ECMO was achieved by reduction of sweep gas flow (43%) and blood flow (21%). No difference was seen in weaning strategy between centers that used a protocol and centers that did not have a protocol for ventilator management. Interestingly, 10% of the centers preferred weaning from the ventilator before removal from the ECMO circuit.
Bleeding and Thrombosis on ECMO and Comparison With Pump Types
Exposure to an ECMO circuit increases the risk of bleeding and thrombosis significantly, thereby increasing morbidity and mortality.21–23 To evaluate the bleeding and thrombotic complications, Dalton et al24 analyzed the ELSO registry data from 8 of the Collaborative Pediatric Critical Care Research Network (CPCCRN) centers for a 7-y period (2005–2011). The study outcome was to describe the bleeding and thrombotic complications and survival to hospital discharge. Bleeding complications were defined as intracranial, gastrointestinal, or pulmonary hemorrhage; cannula site bleeding; surgical site bleeding; hemolysis (>50 mg/dL), and disseminated intravascular coagulation. Thrombotic complications were divided into intracranial infarction and clots in the oxygenator, bridge, bladder, hemofilter, or other. The report was a prelude to a prospective evaluation of specific factors related to patient care, ECMO technology, and many other data elements among CPCCRN centers in a rigorous manner to obtain more specific results. Another report focused on the association of pump type used during ECMO, either roller or centrifugal, since many centers are changing modalities.25
Over the study period, there were 2,036 subjects receiving ECMO, of whom 263 were receiving it for congenital diaphragmatic hernia.24 Complications steadily declined for both neonatal and pediatric subjects over the study years (trend P < .001). Bleeding complications occurred in 33% of neonates and 45% of pediatric subjects other than congenital diaphragmatic hernia. The most common bleeding events included surgical site bleeding, cannula site bleeding, and intracranial hemorrhage. Bleeding and thrombotic complications were associated with decreased survival. In subjects requiring ECMO for congenital diaphragmatic hernia, bleeding and thrombotic complications occurred in 45 and 60%, respectively.
In 2010–2011, there was a change in pump technology, with many centers moving from roller head pumps to centrifugal pumps. To compare the bleeding complications between the 2 pump technologies, a single-center study from the University of Michigan examined adult subjects receiving ECMO support for ≥5 d from 2002 to 2013.25 Of 95 adults, 47 were supported with the roller pump, and 48 of them received centrifugal pump support. There was no difference in the bleeding complications between the 2 pump types. However, when complications were grouped as surgical (cannulation site and surgical site) versus non-surgical bleeding (pulmonary, gastrointestinal, and neurological), there was a higher incidence of non-surgical bleeding with the centrifugal pump. Survival to decannulation and survival to hospital discharge were both higher with roller head pumps.
Early Mobilization of Patients Receiving ECMO
Given the high morbidity of patients in the ICU with muscle weakness, decubiti, and other adverse events, coupled with new ECMO technology that makes patient movement easier and potentially safer, there is a strong effort to minimize sedation and allow patients to be awake, even walking and participating in physical therapy.26,27 In the early days, ECMO was accomplished by heavy sedation and most often by neuromuscular blockade because patients were considered very unstable. With advances in technology and longer duration of ECMO and as patients are being supported as a bridge to transplant, early mobilization has become very important. Small case series with reports of extubation and early tracheostomy with ambulation is being increasingly utilized.
Abrams et al28 conducted a retrospective review of one center's experience with early ambulation with a subset of their ECMO patients being managed by a multidisciplinary team. These 35 subjects mainly included individuals with respiratory failure either as a bridge to transplant or bridge to recovery from their respiratory illness. They used a mobilization scale of 1–8 with 1 being no mobilization or passive range of motion and 8 being full ambulation. Subjects were assessed for suitability by the medical team, followed by evaluation by a physical therapist/occupational therapist for level of activity. They were then prepared for the activity, and then therapy was initiated. Survival was 53% in the bridge to transplant group and 88% in the bridge to recovery group with an average ECMO time of 13.8 ± 7.8 and 9.1 ± 2.6 d in each of the groups, respectively. There was also an increase in participation in physical therapy from the start of the program in 2009 to 2011. They did not have any patient- or circuit-related complications.28
Hospital Volume of ECMO Cases and Mortality
Providing ECMO support requires experienced skilled personnel. There has been a significant rise in the number patients being supported by ECMO and, with that, a growing number of centers, particularly for adult patients. This has raised some concerns regarding rapid diffusion of low-volume advanced care modalities compromising efficacy and effectiveness. One fairly recent white paper of international ECMO experts recommended that ECMO centers providing adult respiratory ECMO should perform at least 20 cases annually.29 Also, some recent pediatric studies have shown that higher ECMO volume is associated with lower mortality.30
A study by Barbaro et al31 examined the international ELSO registry to evaluate the relationship between ECMO volume and mortality in 3 different age groups that included neonatal, pediatric, and adult subjects from January of 1989 to December of 2013. Volume was divided into 4 categories based on yearly patient cases reported to ELSO: <6, 6–14, 15–30, and >30. With the volume of cases as a continuous variable, higher ECMO volume was associated with lower in-hospital mortality in neonatal and adult subjects but not in pediatric subjects using a hierarchical regression model. When single level regression analysis was used, a difference was also noted in the pediatric age group. A subgroup analysis was done for the years 2008–2013 to account for advancement in technology and expansion in the number of adults, which showed that the volume-outcome relationship persisted for adults but not for neonatal or pediatric age groups. In a contrasting report32, propensity core matching looking at ECMO support for children with congenital heart disease, no relationship was found between ECMO volume and mortality. However, low volume was defined as 0–30 cases/y, medium volume was 31–50 cases/y, and high volume was >50 cases/y.
Refractory Cardiac Arrest and ECMO (CHEER Trial)
Both in-hospital and out-of-hospital cardiac arrest carry significant mortality. Use of ECMO in cardiopulmonary resuscitation (CPR) has been proposed by the American Heart Association, and ECMO has been successfully used in pediatric and neonatal CPR with good outcomes.33 The CHEER trial (cardiac arrest, hypothermia, ECMO, early reperfusion) was a prospective pilot study of a treatment protocol from Australia to examine whether ECMO in a specified algorithm of resuscitation improved outcome.34 Patients with out-of-hospital cardiac arrest were eligible if they met the following criteria: (1) age 18–65 y; (2) cardiac arrest due to suspected cardiac etiology; (3) chest compressions commenced within 10 min by bystanders; (4) initial cardiac arrest rhythm of ventricular fibrillation; and (5) mechanical CPR machine available. Patients with in-hospital cardiac arrest were also considered if the underlying cardiac arrest was thought to be reversible and had no significant co-morbidities and underlying neurological disability. Subjects with out-of-hospital cardiac arrest were transported to the Alfred Hospital with mechanical chest compressions and given rapid infusion of 2 L of ice-cold saline. Subjects with in-hospital cardiac arrest also had CPR with a mechanical CPR device and were cooled. Subjects were percutaneously cannulated via the femoral artery (15 French) and vein (17 French) by 2 critical care physicians. A heparin bolus was given once cannula placement was achieved and ECMO flows were established. Cooling was continued at 33°C for another 24 h, followed by slow rewarming of 0.25°C every hour. A distal limb perfusion catheter was inserted as soon as the subject was in the ICU. A total of 26 subjects had ECPR, with 11 out-of-hospital cardiac arrests and 15 in-hospital cardiac arrests. They had 14 survivors and 12 non-survivors. Average time from collapse to initiation of ECMO was 40 min in the survivors and 78 min in non-survivors. Higher survival was obtained in the in-hospital cardiac arrest compared with out-of-hospital cardiac arrest. All survivors were discharged home directly with full neurological recovery. The authors suggest that an overall protocolized approach to ECPR appears to be associated with good outcome.
Summary
ECMO is a rapidly advancing technology with rapid expansion of its use, particularly in adults. ECMO has claimed its role in management algorithms of a number of diseases, such as ARDS and sepsis, and CPR. Challenges of bleeding and thrombosis still exist and are ongoing. Advances in technology have made it possible for patients to be supported for long durations with the ability to ambulate while receiving ECMO. The rapid expansion of this complex critical therapy in centers with few or many patients has raised the issue of volume-outcome and suggestions for regionalization. Many new reports of ECMO and related patient care are appearing, and the brief excerpts presented here will hopefully encourage readers to seek out full publications and review results.
Footnotes
- Correspondence: Heidi J Dalton MD, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042. E-mail: Heidi.dalton{at}inova.org.
Dr Dalton presented a version of this paper at the Year in Review 2015 of the AARC Congress 2015, held November 7–10, 2015, in Tampa, Florida.
Dr Dalton has disclosed relationships with Innovative ECMO Concepts Inc and Maquet. Dr Raman has disclosed no conflicts of interest.
- Copyright © 2016 by Daedalus Enterprises